{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:56:23Z","timestamp":1782100583161,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2010,9,5]],"date-time":"2010-09-05T00:00:00Z","timestamp":1283644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s00262-010-0914-1","type":"journal-article","created":{"date-parts":[[2010,9,4]],"date-time":"2010-09-04T08:19:39Z","timestamp":1283588379000},"page":"1877-1884","source":"Crossref","is-referenced-by-count":65,"title":["Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers"],"prefix":"10.1007","volume":"59","author":[{"given":"Melissa A.","family":"Geller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Argenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levi S.","family":"Downs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda F.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahel","family":"Ghebre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Panoskaltsis-Mortari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Curtsinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,5]]},"reference":[{"key":"914_CR1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","volume":"20","author":"AM Krieg","year":"2002","unstructured":"Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709\u2013760","journal-title":"Annu Rev Immunol"},{"key":"914_CR2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.molimm.2004.09.037","volume":"42","author":"I Kokkinopoulos","year":"2005","unstructured":"Kokkinopoulos I, Jordan WJ, Ritter MA (2005) Toll-like receptor mRNA expression patterns in human dendritic cells and monocytes. Mol Immunol 42:957\u2013968","journal-title":"Mol Immunol"},{"key":"914_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0192-0561(98)00068-X","volume":"21","author":"RL Miller","year":"1999","unstructured":"Miller RL, Gerster JF, Owens ML et al (1999) Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 21:1\u201314","journal-title":"Int J Immunopharmacol"},{"key":"914_CR4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1128\/AAC.32.5.678","volume":"32","author":"M Chen","year":"1988","unstructured":"Chen M, Griffith BP, Lucia HL, Hsiung GD (1988) Efficacy of S26308 against guinea pig cytomegalovirus infection. Antimicrob Agents Chemother 32:678\u2013683","journal-title":"Antimicrob Agents Chemother"},{"key":"914_CR5","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1086\/319262","volume":"183","author":"DI Bernstein","year":"2001","unstructured":"Bernstein DI, Harrison CJ, Tomai MA, Miller RL (2001) Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J Infect Dis 183:844\u2013849","journal-title":"J Infect Dis"},{"key":"914_CR6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","volume":"3","author":"H Hemmi","year":"2002","unstructured":"Hemmi H, Kaisho T, Takeuchi O et al (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196\u2013200","journal-title":"Nat Immunol"},{"key":"914_CR7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.0303-6987.2005.00297.x","volume":"32","author":"J Wenzel","year":"2005","unstructured":"Wenzel J, Uerlich M, Haller O et al (2005) Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J Cutan Pathol 32:257\u2013262","journal-title":"J Cutan Pathol"},{"issue":"Suppl 66","key":"914_CR8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.0366-077X.2003.05632.x","volume":"149","author":"T Meyer","year":"2003","unstructured":"Meyer T, Nindl I, Schmook T et al (2003) Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol 149(Suppl 66):9\u201314","journal-title":"Br J Dermatol"},{"key":"914_CR9","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1158\/1078-0432.CCR-07-1443","volume":"13","author":"AZYC Dudek","year":"2007","unstructured":"Dudek AZYC, Harrison LI, Kumar S, Hawkinson R et al (2007) First in human phase I trial of 852A, a novel systemic Toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 13:7119\u20137125","journal-title":"Clin Cancer Res"},{"key":"914_CR10","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1177\/0091270007303766","volume":"47","author":"LI Harrison","year":"2007","unstructured":"Harrison LI, Astry C, Kumar S, Yunis C (2007) Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol 47:962\u2013969","journal-title":"J Clin Pharmacol"},{"key":"914_CR11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.0906-6705.2006.00414.x","volume":"15","author":"M Schiller","year":"2006","unstructured":"Schiller M, Metze D, Luger TA et al (2006) Immune response modifiers\u2014mode of action. Exp Dermatol 15:331\u2013341","journal-title":"Exp Dermatol"},{"key":"914_CR12","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4049\/jimmunol.174.3.1259","volume":"174","author":"KB Gorden","year":"2005","unstructured":"Gorden KB, Gorski KS, Gibson SJ et al (2005) Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 174:1259\u20131268","journal-title":"J Immunol"},{"key":"914_CR13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1096\/fasebj.12.9.705","volume":"12","author":"V Gangur","year":"1998","unstructured":"Gangur V, Simons FE, Hayglass KT (1998) Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses. Faseb J 12:705\u2013713","journal-title":"Faseb J"},{"key":"914_CR14","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20011983","volume":"195","author":"H Yoneyama","year":"2002","unstructured":"Yoneyama H, Narumi S, Zhang Y et al (2002) Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. J Exp Med 195:1257\u20131266","journal-title":"J Exp Med"},{"key":"914_CR15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","volume":"75","author":"K Schroder","year":"2004","unstructured":"Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163\u2013189","journal-title":"J Leukoc Biol"},{"key":"914_CR16","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.4049\/jimmunol.155.8.3877","volume":"155","author":"DD Taub","year":"1995","unstructured":"Taub DD, Sayers TJ, Carter CR, Ortaldo JR (1995) Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol 155:3877\u20133888","journal-title":"J Immunol"},{"key":"914_CR17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3233\/BD-2002-15109","volume":"15","author":"ML Disis","year":"2002","unstructured":"Disis ML (2002) Immunologic targets for breast cancer. Breast Dis 15:83\u201390","journal-title":"Breast Dis"},{"key":"914_CR18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10549-005-7017-2","volume":"94","author":"UR Hengge","year":"2005","unstructured":"Hengge UR, Roth S, Tannapfel A (2005) Topical imiquimod to treat recurrent breast cancer. Breast Cancer Res Treat 94:93\u201394","journal-title":"Breast Cancer Res Treat"},{"key":"914_CR19","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1016\/j.vaccine.2005.04.017","volume":"23","author":"M Adams","year":"2005","unstructured":"Adams M, Navabi H, Croston D et al (2005) The rationale for combined chemo\/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 23:2374\u20132378","journal-title":"Vaccine"},{"key":"914_CR20","first-page":"3031","volume":"7","author":"C Diaz-Arrastia","year":"2001","unstructured":"Diaz-Arrastia C, Arany I, Robazetti SC et al (2001) Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. Clin Cancer Res 7:3031\u20133033","journal-title":"Clin Cancer Res"},{"key":"914_CR21","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1158\/1078-0432.CCR-07-1938","volume":"14","author":"R Dummer","year":"2008","unstructured":"Dummer R, Hauschild A, Becker JC et al (2008) An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 14:856\u2013864","journal-title":"Clin Cancer Res"},{"key":"914_CR22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.1985.3.8.1079","volume":"3","author":"P Bonomi","year":"1985","unstructured":"Bonomi P, Blessing JA, Stehman FB et al (1985) Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3:1079\u20131085","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-010-0914-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-010-0914-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-010-0914-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T04:57:51Z","timestamp":1685768271000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-010-0914-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,5]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["914"],"URL":"https:\/\/doi.org\/10.1007\/s00262-010-0914-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,5]]}}}